Dermatitis, Atopic
FDA Approves Ebglyss (Lebrikizumab-lbkz) for Moderate-to-Severe Atopic Dermatitis in Adults and Children 12 Years and Older
Ebglyss, Lebrikizumab-lbkz, FDA Approval, Moderate-to-Severe Atopic Dermatitis, Eczema Treatment
RAPT Therapeutics Announces Significant Workforce Reduction Following Clinical Hold on Zelnecirnon Trials
RAPT Therapeutics, zelnecirnon, clinical hold, workforce reduction, FDA, clinical trials, atopic dermatitis, asthma, oncology, CCR4 agonist
Almirall’s Ebglyss Gains NICE Recommendation for Atopic Dermatitis Treatment
Ebglyss, lebrikizumab, atopic dermatitis, NICE recommendation, Almirall, NHS England, biological therapy, moderate to severe atopic dermatitis
Arcutis Biotherapeutics Secures FDA Approval for ZORYVE Cream to Treat Atopic Dermatitis
Arcutis Biotherapeutics, ZORYVE, Atopic Dermatitis, FDA Approval, Roflumilast Cream, Steroid-Free Treatment
Johnson & Johnson Expands Dermatology Portfolio with $850M Acquisition of Proteologix
Johnson & Johnson, J&J, Proteologix, atopic dermatitis, bispecifics, pipeline, acquisition, $850M
Sanofi Eyes COPD Treatment as Major Growth Driver for Dupixent, Says CEO
Sanofi, Dupixent, COPD, growth pillar, immunology, CEO, treatment, expansion, clinical trials, asthma, atopic dermatitis.